Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02913092Not ApplicableCompleted

Electronic Monitoring of Medication Adherence in Moderate to Severe Asthma Patients

Role: collaborator

NCT03008915Phase 2Completed

Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency

Role: collaborator

NCT00911794Not ApplicableCompleted

Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease

Role: collaborator

All 3 trials loaded